CN113632855A - Pecan oil composition with blood fat reducing function and preparation method thereof - Google Patents
Pecan oil composition with blood fat reducing function and preparation method thereof Download PDFInfo
- Publication number
- CN113632855A CN113632855A CN202110706888.0A CN202110706888A CN113632855A CN 113632855 A CN113632855 A CN 113632855A CN 202110706888 A CN202110706888 A CN 202110706888A CN 113632855 A CN113632855 A CN 113632855A
- Authority
- CN
- China
- Prior art keywords
- oil composition
- pecan oil
- blood fat
- pecan
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000019495 Pecan oil Nutrition 0.000 title claims abstract description 67
- 239000010470 pecan oil Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 210000004369 blood Anatomy 0.000 title claims abstract description 53
- 239000008280 blood Substances 0.000 title claims abstract description 53
- 230000001603 reducing effect Effects 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 18
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 17
- 235000012661 lycopene Nutrition 0.000 claims abstract description 17
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 17
- 239000001751 lycopene Substances 0.000 claims abstract description 17
- 229960004999 lycopene Drugs 0.000 claims abstract description 17
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 17
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 241000723418 Carya Species 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 13
- 229940083466 soybean lecithin Drugs 0.000 claims description 13
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 3
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 238000010411 cooking Methods 0.000 claims 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 9
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 6
- 108090001030 Lipoproteins Proteins 0.000 abstract description 4
- 102000004895 Lipoproteins Human genes 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 210000004165 myocardium Anatomy 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 38
- 108010023302 HDL Cholesterol Proteins 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 26
- 108010028554 LDL Cholesterol Proteins 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 22
- 235000009200 high fat diet Nutrition 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 239000010495 camellia oil Substances 0.000 description 9
- 235000020927 12-h fasting Nutrition 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 238000005303 weighing Methods 0.000 description 6
- 229930182558 Sterol Natural products 0.000 description 5
- 150000003432 sterols Chemical class 0.000 description 5
- 235000003702 sterols Nutrition 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000020828 fasting Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
- A23D9/04—Working-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the technical field of preparation of functional health-care foods, and particularly relates to a pecan oil composition with a blood fat reducing function and a preparation method thereof. The pecan oil composition disclosed by the invention has the effects of reducing oxidation of blood vessel intimal lipoprotein, removing free radicals of a human body, regulating blood fat, reducing cholesterol, improving metabolic capability of the human body and the like by mainly matching with lycopene, and has good effects of enhancing organism endurance, improving immunity, improving blood circulation, enhancing skin cell activity and the like by assisting vitamin E, so that the pecan oil composition disclosed by the invention can prevent cardiovascular diseases and improve the function of cardiac muscle and has a good blood fat reducing effect.
Description
Technical Field
The invention belongs to the technical field of preparation of functional health-care foods, and particularly relates to a pecan oil composition with a blood fat reducing function and a preparation method thereof.
Background
Hyperlipidemia refers to the condition of high blood cholesterol (TC) and/or Triglyceride (TG) or low high density lipoprotein cholesterol (HDL-C), and is called dyslipidemia in modern medicine, is the most main risk factor of cardiovascular diseases caused by systemic diseases, often causes complications of organs such as heart, brain, kidney and the like, and seriously harms the health of human beings. Its direct damage is the acceleration of systemic atherosclerosis, and it is known that important organs throughout the body are supplied with blood and oxygen by arteries, which can have serious consequences once the atheromatous plaque is blocked.
In addition, arteriosclerosis also causes renal failure. A large number of research data show that hyperlipidemia is an important risk factor for cerebral apoplexy, coronary heart disease, myocardial infarction and sudden cardiac death.
Referring to cardiovascular disease, many people are known to be associated with hypertension, but in fact, hidden in our bodies, there is a more concealed, more serious "killer" that is hyperlipidaemia that is threatening our vascular health at all times. Experts point out that dyslipidemia is one of important risk factors for cardiovascular and cerebrovascular diseases such as coronary heart disease, myocardial infarction, ischemic stroke and the like. Patients with hyperlipidemia must be found and treated early. Therefore, the understanding of hypertension is improved, and the Chinese medicinal composition has extremely important significance for early prevention and timely treatment. The modern medicine for treating hyperlipidemia generally has the following sequence: the food therapy, the tea therapy, the health care and the traditional Chinese medicine are finally selected by western medicines which are not very useful. In order to control hyperlipidemia, various methods have been devised in addition to taking medicines.
Disclosure of Invention
The invention aims to solve the problems in the prior art and provides a pecan oil composition with rich nutrient components and simple preparation method and a blood fat reducing function.
The purpose of the invention can be realized by the following technical scheme:
a pecan oil composition with a function of reducing blood fat comprises the following raw materials in parts by weight: 65-95 parts of hickory oil, 1-8 parts of lycopene, 2-8 parts of soybean lecithin, 0.5-0.8 part of vitamin E and 5-15 parts of auxiliary materials.
Preferably, the composition comprises the following raw materials in parts by weight: 70-90 parts of hickory oil, 3-5 parts of lycopene, 4-6 parts of soybean lecithin, 0.5-0.6 part of vitamin E and 5-10 parts of auxiliary materials.
Lycopene is extracted from fruit and pericarp of tomato, and is the most powerful antioxidant in nature, with antioxidant effect 2 times that of carotene and 100 times that of VE. Lycopene has a stronger effect than beta-carotene in clearing free radicals of human body. Lycopene has a remarkable effect in protecting cardiovascular vessels, and lipoprotein oxidation in the intima of blood vessels is a key factor in the development and development of atherosclerosis. Lycopene plays an important role in reducing lipoprotein oxidation. The pecan oil composition disclosed by the invention can reduce serum cholesterol by taking the pecan oil as a main component and adding lycopene, so that the pecan oil composition disclosed by the invention can be used for preventing and treating hyperlipidemia and relieving cardiovascular diseases.
In the pecan oil composition with the function of reducing blood fat, the auxiliary material is one or more of sucrose fatty acid ester and polyethylene glycol 400.
In the pecan oil composition with the function of reducing blood fat, the content of phytosterol in the pecan oil is not less than 10000mg/L, and the content of unsaturated fatty acid is not less than 80%.
In the pecan oil composition with the function of reducing blood fat, the soybean lecithin comprises 20-30% of phosphatidylcholine, 15-25% of cephalin and 10-20% of inositol phospholipid. The invention adds soybean lecithin to make pecan oil composition delay senility, strengthen self-healing ability and regeneration ability of antibody tissue, enhance vitality of human body, delay senility, regulate blood fat and reduce cholesterol, further prevent and treat coronary heart disease, hypertension, myocardial infarction, cerebral thrombosis, cerebral hemorrhage, arteriosclerosis and other diseases, and can also strengthen brain and intelligence and prevent senile dementia.
The invention also provides a preparation method of the pecan oil composition with the function of reducing blood fat, which comprises the following steps:
s1, drying the hickory oil seeds, removing shells, crushing, moistening, steaming, frying, squeezing to obtain a crude hickory oil product, refining to obtain edible hickory oil, and adding phytosterol to obtain the hickory oil;
s2, preparing raw materials;
s3, adding the pecan oil, the lycopene and the soybean lecithin into the auxiliary materials, and then adding the vitamin E for homogenizing and mixing to obtain a powdery mixture;
s4, pressing the powder mixture to obtain the pecan oil composition.
Preferably, in step S1, fresh pecan oil seeds are dried, the pecan oil seeds are shelled, then the pecan oil seeds are processed into powder by a pulverizer, the powder is wetted by steam or water spray to be 'wet-steamed and fried', a tea oil crude product is prepared by squeezing by a screw press, then the tea oil crude product is refined to obtain edible tea oil, and the tea oil is added with phytosterol until the sterol content in the tea oil is detected to be higher than 10000mg/L, so that the pecan oil is obtained.
Preferably, the refining step includes deacidification, washing with water, and purification of a smell.
In the preparation method of the pecan oil composition with the function of reducing blood fat, the water content of the dried pecan oil seeds in the step S1 is 5-6%.
In the preparation method of the pecan oil composition with the function of reducing blood fat, the steaming and frying temperature of the step S1 is 130-140 ℃, and the water content of the pecan oil seeds after steaming and frying is 3-4%.
In the preparation method of the pecan oil composition with the function of reducing blood fat, the temperature of the homogenized material mixing in the step S3 is 30-70 ℃, and the pressure is 15-25 Mpa. The invention is characterized in that the materials are mixed homogeneously at 30-70 deg.C, which is beneficial to the mixing of the components, and the temperature is not very high, which can ensure the chemical stability of the components. Under 15-25MPa, the material is easy to homogenize fast, and the material is homogeneous and single phase mixture comprising dispersed and inhomogeneous multiphase mixture.
In the above preparation method of the pecan oil composition having the function of reducing blood lipid, the pecan oil composition prepared by the pressing method of step S4 is a capsule.
Preferably, the method for preparing the capsule by the compression method comprises the following steps:
firstly, according to the formula of a capsule wall material, putting gelatin into distilled water for soaking to swell, adding other materials together after the gelatin is dissolved, and stirring and mixing uniformly;
secondly, taking out the prepared capsule wall glue solution, coating the capsule wall glue solution on the surface of a flat plate to ensure that the thickness is uniform, and then heating the capsule wall glue solution at the temperature of about 90 ℃ to evaporate the water on the surface to form a soft film with certain toughness and certain elasticity;
thirdly, pressing the soft capsules; when in small-batch production, the mixture is manually pressed by a pill pressing die; in mass production, an automatic rotary bag rolling machine is often adopted for production.
Compared with the prior art, the invention has the following beneficial effects:
the pecan oil composition disclosed by the invention has the effects of reducing oxidation of blood vessel intimal lipoprotein, removing free radicals of a human body, regulating blood fat, reducing cholesterol, improving metabolic capacity of the human body and the like by mainly matching with lycopene, and has good effects in the aspects of enhancing organism endurance, improving immunity, improving blood circulation, enhancing skin cell activity and the like by assisting vitamin E, so that the pecan oil composition disclosed by the invention can prevent cardiovascular diseases, improve the function of cardiac muscle and has a good blood fat reducing effect.
Detailed Description
The following are specific examples of the present invention and further describe the technical solutions of the present invention, but the present invention is not limited to these examples.
Example 1:
s1, drying fresh pecan oil seeds, controlling the water content to be 5-6%, shelling, crushing, moistening, steaming and frying at 135 ℃, controlling the water content to be 3-4%, squeezing to obtain a pecan oil crude product, deacidifying, washing with water, and removing odor to obtain edible pecan oil, detecting the content of unsaturated fatty acids in the tea oil to be not less than 80%, and the content of sterols to be not less than 1000mg/L, adding phytosterol, and stirring uniformly until the content of sterols in the tea oil is detected to be more than 10000mg/L to obtain the pecan oil;
s2, preparing raw materials according to the following components: 80 parts of hickory oil, 5 parts of lycopene, 4.5 parts of soybean lecithin, 0.5 part of vitamin E and 10 parts of sucrose fatty acid ester.
S3, adding the pecan oil, the lycopene and the soybean lecithin into the auxiliary materials, and then adding the vitamin E into the auxiliary materials to carry out homogeneous mixing at 50 ℃ and 20MPa to obtain a bulk mixture;
s4, pressing the dough mixture to obtain the pecan oil composition.
Example 2:
s1, drying fresh pecan oil seeds, controlling the water content to be 5-6%, shelling, crushing, moistening, steaming and frying at 135 ℃, controlling the water content to be 3-4%, squeezing to obtain a pecan oil crude product, deacidifying, washing with water, and removing odor to obtain edible pecan oil, detecting the content of unsaturated fatty acids in the tea oil to be not less than 80%, and the content of sterols to be not less than 1000mg/L, adding phytosterol, and stirring uniformly until the content of sterols in the tea oil is detected to be more than 10000mg/L to obtain the pecan oil;
s2, preparing raw materials according to the following components: 85 parts of hickory oil, 4 parts of lycopene, 4.5 parts of soybean lecithin, 0.5 part of vitamin E and 6 parts of sucrose fatty acid ester.
S3, adding the pecan oil, the lycopene and the soybean lecithin into the auxiliary materials, and then adding the vitamin E into the auxiliary materials to carry out homogeneous mixing at 50 ℃ and 20MPa to obtain a powdery mixture;
s4, pressing the dough mixture to obtain the pecan oil composition.
Application example 1:
taking 10 SPF male ICR mice, pre-feeding for 1 week, fasting for 12h, taking blood and measuring blood lipid, preparing the compound hickory oil of example 1 at a dose of 0.5 g/kg-1Continuously administering the low dose for 4 weeks, wherein high-fat feed is administered, fasting the mice for 12h at 2 and 4 weeks, weighing, collecting blood from orbit, centrifuging at 3000RPM for 10min to separate serum, measuring TC, HDL-C and LDL-C levels of serum by a full-automatic biochemical analyzer, and calculating comprehensive index of blood lipid; at 4 weeks of dosing, livers were weighed and liver indices were calculated.
Application example 2:
taking 10 SPF male ICR mice, pre-feeding for 1 week, fasting for 12h, taking blood and measuring blood lipid, preparing the compound hickory oil of example 1 at a ratio of 1.0 g/kg-1Continuously administering the medium dose for 4 weeks, wherein high-fat feed is administered, fasting for 12h for each group of mice at 2 and 4 weeks, weighing, collecting blood from orbit, centrifuging at 3000RPM for 10min to separate serum, measuring TC, HDL-C and LDL-C levels of serum by using a full-automatic biochemical analyzer, and calculating comprehensive index of blood lipid; at 4 weeks of dosing, livers were weighed and liver indices were calculated.
Application example 3:
taking 10 SPF male ICR mice, pre-feeding for 1 week, fasting for 12h, taking blood and measuring blood lipid, preparing the compound hickory oil of example 1 at a ratio of 2.0 g/kg-1Continuously administering high dose for 4 weeks, wherein high fat feed is administered, fasting for 12h for each group of mice at 2 and 4 weeks, weighing, collecting blood from orbit, centrifuging at 3000RPM for 10min to separate serum, measuring TC, HDL-C and LDL-C levels of serum with full-automatic biochemical analyzer, and calculating comprehensive index of blood lipid; taking at 4 weeks of administrationLiver weighing and calculating liver index.
Application comparative example 1:
the preparation method of the 2 percent sucrose fatty ester solution comprises the following steps: 20g of sucrose fatty acid ester (manufactured by Mitsubishi corporation, 0Z10940A) was added to 1000ml of 98 ℃ distilled water, and the mixture was stirred and dispersed by a homogenizer, cooled, and stored at 4 ℃.
Taking 10 SPF male ICR mice, pre-feeding for 1 week, fasting for 12h, taking blood for measuring blood lipid, preparing 2% sucrose fatty ester solution at a ratio of 10 mL/kg-1Continuously feeding high-fat feed for 4 weeks, fasting for 12h, weighing, collecting blood from orbit, centrifuging at 3000RPM for 10min, separating serum, measuring TC, HDL-C and LDL-C levels of serum with full-automatic biochemical analyzer, and calculating blood lipid comprehensive index; at 4 weeks of dosing, livers were weighed and liver indices were calculated.
Application example 2:
the preparation method of the 2 percent sucrose fatty ester solution comprises the following steps: 20g of sucrose fatty acid ester (manufactured by Mitsubishi corporation, 0Z10940A) was added to 1000ml of 98 ℃ distilled water, and the mixture was stirred and dispersed by a homogenizer, cooled, and stored at 4 ℃.
Taking 10 SPF male ICR mice, pre-feeding for 1 week, fasting for 12h, taking blood for measuring blood lipid, preparing 2% sucrose fatty ester solution at a ratio of 10 mL/kg-1Continuously feeding common feed for 4 weeks, fasting each group of mice for 12h at 2 and 4 weeks, weighing, collecting blood from orbit, centrifuging at 3000RPM for 10min to separate serum, measuring TC, HDL-C and LDL-C levels of serum with full-automatic biochemical analyzer, and calculating comprehensive index of blood lipid; at 4 weeks of dosing, livers were weighed and liver indices were calculated.
Body weight and liver index determination: body weight, liver weight and liver index of each group of mice at 0, 2, 4 weeks of administration.
And (3) blood fat determination: the whole blood was centrifuged at 3000r/min for 10min to separate serum, and total serum cholesterol (TC), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were measured using a full-automatic biochemical analyzer. And the blood lipid complex index [ LDL-C/HDL-C and arteriosclerosis index AI ═ TC-HDL-C/HDL-C ] was calculated from the measurement results.
Data processing: statistical analysis was performed using SPSS11.5 software, all data expressed as means. + -. standard deviation (X. + -.S), and the data were measured and the results evaluated using the t-test.
Table 1: using examples 1-3, using comparative examples 1-2 rats varied in body weight over different dosing periods (g, n-10,
)
table 2: using examples 1-3, using comparative examples 1-2, the change in serum TC at different dosing stages in rats (mmol/L, n-10,
)
| application examples | Before administration | The administration is carried out for 2 weeks | Administration for 4 weeks |
| Application comparative example 1 | 2.35±0.46 | 6.49±1.12 | 5.60±0.83 |
| Comparative application example 2 | 2.36±0.21 | 2.50±0.16 | 2.53±0.14 |
| Application example 1 | 2.42±0.41 | 5.69±0.80 | 5.26±0.91 |
| Application example 2 | 2.36±0.26 | 5.62±0.51 | 4.78±0.82 |
| Application example 3 | 2.35±0.20 | 5.56±0.84 | 4.72±0.44 |
Table 3: using examples 1-3, using comparative examples 1-2, the change in serum HDL-C in rats at different stages of administration (mmol/L, n-10,
)
table 4: using examples 1-3, using comparative examples 1-2 the change in serum LDL-C at different dosing stages in rats (mmol/L, n-10,
)
| application examples | Before administration | The administration is carried out for 2 weeks | Administration for 4 weeks |
| Application comparative example 1 | 0.51±0.15 | 2.51±0.78 | 2.08±0.52 |
| Comparative application example 2 | 0.49±0.13 | 0.06±0.02 | 0.09±0.03 |
| Application example 1 | 0.54±0.22 | 2.11±0.63 | 1.79±0.59 |
| Application example 2 | 0.47±0.17 | 1.99±0.59 | 1.56±0.36 |
| Application example 3 | 0.48±0.17 | 1.90±0.41 | 1.51±0.30 |
Table 5: using examples 1-3 and comparative examples 1-2, the change in the serum HDL-C/TC ratio at different dosing stages in rats (n-10,
)
table 6: using examples 1-3 and comparative examples 1-2, the change in serum LDL-C/HDL-C ratio at different dosing stages in rats (n-10,
)
| application examples | Before administration | The administration is carried out for 2 weeks | Administration for 4 weeks |
| Application comparative example 1 | 0.293±0.094 | 0.780±0.204 | 0.745±0.128 |
| Comparative application example 2 | 0.304±0.074 | 0.035±0.010 | 0.048±0.016 |
| Application example 1 | 0.325±0.105 | 0.722±0.209 | 0.627±0.166 |
| Application example 2 | 0.299±0.134 | 0.673±0.275 | 0.593±0.178 |
| Application example 3 | 0.299±0.103 | 0.622±0.126 | 0.580±0.137 |
Table 7: using examples 1-3, using comparative examples 1-2, the change in the serum arteriosclerosis index AI of the rats at different administration stages (n-10,
)
table 8: using examples 1-3, using comparative examples 1-2, the change in liver weight and liver index for different dosing stages of rats (g, g/Kg, n-10,
)
| application examples | Liver weight (g) | Liver index (g/kg) |
| Application comparative example 1 | 2.357±0.432 | 71.40±14.91 |
| Comparative application example 2 | 1.466±0.140 | 43.58±2.82 |
| Application example 1 | 1.834±0.180 | 54.66±6.98 |
| Application example 2 | 1.892±0.224 | 57.62±7.87 |
| Application example 3 | 1.968±0.393 | 59.95±10.72 |
As can be seen from table 2, compared with the application comparative example 2, the total cholesterol in the serum of the mouse has no significant difference when the mouse is fed with the high fat feed in the application comparative example 1, and the total cholesterol in the serum of the mouse is significantly increased when the mouse is fed with the high fat feed for 2 weeks and 4 weeks; compared with application comparative example 1, the mice in the administration group had no significant difference in total cholesterol in serum before the administration of the high fat diet, and were fed with the high fat diet while 0.5, 1.0, 2.0 g/kg-1The pecan oil composition of (1) in the high dose group (2.0 g/kg)-1) The total cholesterol in the serum is obviously reduced when the mice are administrated for 2 and 4 weeks, and the medium dose group (1.0 g.kg)-1) Serum total cholesterol was significantly reduced at 4 weeks of administration.
As can be seen from Table 3, compared with the application comparative example 2, the HDL-C in the serum of the mouse in the application comparative example 1 was not significantly different before the administration of the high fat diet, and the HDL-C in the serum of the mouse was significantly increased at 2 weeks and 4 weeks after the administration of the high fat diet; compared with application comparative example 1, 0.5, 1.0, 2.0 g.kg were given-1After the pecan oil composition is used, no obvious difference exists in HDL-C in serum of mice in an administration group.
As can be seen from Table 4, as compared with the application comparative example 2, before the administration of the high fat diet, there was no significant difference in LDL-C in the serum of the mice in the application comparative example 1, and LDL-C in the serum of the mice was significantly increased at 2 weeks and 4 weeks after the administration of the high fat diet; compared with application comparative example 1, before the administration of the high-fat feed, the mice in the administration group have no obvious difference of LDL-C in the blood serum, and are fed with the high-fat feed and simultaneously fed with 0.5, 1.0 and 2.0 g/kg-1The hickory oil composition of (2.0 g.kg)-1) LDL-C in serum was significantly reduced at 2 and 4 weeks of administration to mice, and the medium dose group (1.0 g. kg)-1) LDL-C in serum was significantly reduced at 4 weeks of administration.
As can be seen from Table 5, the feeding was high as compared with the comparative example 2Before the fat feed is applied, the HDL-C/TC ratio in the blood serum of the mouse has no obvious difference by using the comparative example 1, and the HDL-C/TC ratio in the blood serum of the mouse is obviously reduced when the mouse is fed with the high-fat feed for 2 weeks and 4 weeks; compared with application comparative example 1, the mice in the administration group had no significant difference in HDL-C/TC ratio in serum before administration of the high fat diet, and were fed with the high fat diet while being administered with 0.5, 1.0, 2.0 g/kg-1The low, medium and high dose groups (0.5, 1.0, 2.0 g.kg) after the composition of the wild walnut oil-1) The HDL-C/TC ratio in serum is obviously increased at 4 weeks of administration to mice.
As is clear from Table 6, compared with the comparative example 2, there was no significant difference in the LDL-C/HDL-C ratio in the serum of the mouse in the comparative example 1 before the administration of the high-fat diet, and the LDL-C/HDL-C ratio in the serum of the mouse was significantly increased at 2 weeks and 4 weeks after the administration of the high-fat diet; compared with application comparative example 1, the mice in the administration group had no significant difference in LDL-C/HDL-C ratio in serum before administration of the high fat diet, and were fed with the high fat diet while being administered with 0.5, 1.0, 2.0 g/kg-1The pecan oil composition of (1) in the high dose group (2.0 g/kg)-1) The ratio of LDL-C/HDL-C in serum is obviously reduced at 2 and 4 weeks of administration of the mice, and the middle dose group (1.0g kg)-1) The LDL-C/HDL-C ratio in serum was significantly reduced at 4 weeks of administration.
As can be seen from table 7, compared with the application comparative example 2, before the administration of the high fat diet, the arteriosclerosis indexes of the mice of the application comparative example 1 were not significantly different, and the arteriosclerosis indexes of the mice were significantly increased at 2 weeks and 4 weeks after the administration of the high fat diet; compared with application comparative example 1, before feeding the high-fat feed, the arteriosclerosis indexes of mice in the administration group have no obvious difference, and the high-fat feed is fed while 0.5, 1.0 and 2.0 g.kg-1The hickory oil composition of (2.0 g.kg)-1) The arteriosclerosis index of mice is obviously reduced at 2 and 4 weeks of administration, and the low and medium dose groups (0.5 and 1.0 g.kg)-1) The arteriosclerosis index decreased significantly at 4 weeks of administration.
As shown in table 8, the liver weight and liver index of the mouse are significantly increased in the comparative example 1, compared to the comparative example 2; compared with application comparative example 1, 0.5, 1.0, 2.0 g.kg were given-1The pecan oil composition of (1.0g, 0.5g, 1.0 g) was added to the low, medium and high dose groups·kg-1) The weight of liver was significantly reduced at 4 weeks of administration to mice, and the low and medium dose groups (0.5, 1.0 g.kg)-1) Liver index decreased significantly at 4 weeks of dosing.
The results preliminarily show that the pecan oil can obviously reduce the TC, LDL-C level, LDL-C/HDL-C ratio, AI index, liver weight and liver index in the serum of a hypercholesteremia mouse, and increase the HDL-C/TC ratio. The pecan oil composition can regulate the metabolic disorder of lipid in vivo, and simultaneously shows that the pecan oil composition can have the effect of preventing atherosclerosis and high-fat fatty liver.
The technical scope of the invention claimed by the embodiments of the present application is not exhaustive, and new technical solutions formed by equivalent replacement of single or multiple technical features in the technical solutions of the embodiments are also within the scope of the invention claimed by the present application; in all the embodiments of the present invention, which are listed or not listed, each parameter in the same embodiment only represents an example (i.e., a feasible embodiment) of the technical solution, and there is no strict matching and limiting relationship between the parameters, wherein the parameters may be replaced with each other without departing from the axiom and the requirements of the present invention, unless otherwise specified. The technical means disclosed by the scheme of the invention are not limited to the technical means disclosed by the technical means, and the technical scheme also comprises the technical scheme formed by any combination of the technical characteristics. While the foregoing is directed to embodiments of the present invention, it will be appreciated by those skilled in the art that various changes may be made in the embodiments without departing from the principles of the invention, and that such changes and modifications are intended to be included within the scope of the invention.
The specific embodiments described herein are merely illustrative of the spirit of the invention. Various modifications or additions may be made to the described embodiments or alternatives may be employed by those skilled in the art without departing from the spirit or ambit of the invention as defined in the appended claims.
Claims (10)
1. The pecan oil composition with the function of reducing blood fat is characterized by comprising the following raw materials in parts by weight: 65-95 parts of hickory oil, 1-8 parts of lycopene, 2-8 parts of soybean lecithin, 0.5-0.8 part of vitamin E and 5-15 parts of auxiliary materials.
2. The pecan oil composition with the function of reducing blood fat according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 70-90 parts of hickory oil, 3-5 parts of lycopene, 4-6 parts of soybean lecithin, 0.5-0.6 part of vitamin E and 5-10 parts of auxiliary materials.
3. The pecan oil composition with the function of reducing blood fat according to claim 1 or 2, wherein the auxiliary material is one or more of sucrose fatty acid ester and polyethylene glycol 400.
4. The pecan oil composition with the function of reducing blood fat according to claim 1 or 2, wherein the pecan oil contains phytosterol in an amount of not less than 10000mg/L and unsaturated fatty acid in an amount of not less than 80%.
5. The pecan oil composition with the function of reducing blood fat according to claim 1 or 2, wherein the soybean lecithin comprises 20-30% of phosphatidylcholine, 15-25% of cephalin and 10-20% of inositol phospholipid.
6. A method for preparing the pecan oil composition with hypolipidemic effect according to claim 1 or 2, comprising the following steps:
s1, drying the hickory oil seeds, removing shells, crushing, moistening, steaming, frying, squeezing to obtain a crude hickory oil product, refining to obtain edible hickory oil, and adding phytosterol to obtain the hickory oil;
s2, preparing raw materials;
s3, adding the pecan oil, the lycopene and the soybean lecithin into the auxiliary materials, and then adding the vitamin E for homogenizing and mixing to obtain a powdery mixture;
s4, pressing the powder mixture to obtain the pecan oil composition.
7. The method for preparing the pecan oil composition with the function of reducing blood fat as claimed in claim 6, wherein the water content of the pecan oil seeds dried in the step S1 is 5% -6%.
8. The method for preparing the pecan oil composition with the function of reducing blood fat as claimed in claim 6, wherein the cooking temperature of the step S1 is 130-140 ℃, and the water content of the pecan oil seeds after cooking is 3-4%.
9. The method for preparing the pecan oil composition with the function of reducing blood fat according to claim 6, wherein the temperature of the homogenized material in the step S3 is 30-70 ℃, and the pressure is 15-25 MPa.
10. The method for preparing the pecan oil composition with the function of reducing blood fat as claimed in claim 6, wherein the pecan oil composition prepared by the pressing method of step S4 is a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110706888.0A CN113632855A (en) | 2021-06-24 | 2021-06-24 | Pecan oil composition with blood fat reducing function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110706888.0A CN113632855A (en) | 2021-06-24 | 2021-06-24 | Pecan oil composition with blood fat reducing function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113632855A true CN113632855A (en) | 2021-11-12 |
Family
ID=78416183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110706888.0A Pending CN113632855A (en) | 2021-06-24 | 2021-06-24 | Pecan oil composition with blood fat reducing function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113632855A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283386A (en) * | 2011-08-16 | 2011-12-21 | 中国林业科学研究院亚热带林业研究所 | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof |
| CN102318829A (en) * | 2011-08-17 | 2012-01-18 | 中国林业科学研究院亚热带林业研究所 | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof |
| CN103392834A (en) * | 2013-08-14 | 2013-11-20 | 山东三星玉米产业科技有限公司 | Nutrition blend oil applicable to middle aged and elderly people and preparation method thereof |
| CN103535710A (en) * | 2012-07-13 | 2014-01-29 | 杭州临安山妹子食品有限公司 | Pecan essential oil capsules and preparation method thereof |
| CN104958345A (en) * | 2015-07-14 | 2015-10-07 | 陈雨 | Soybean lecithin soft capsule with lipid-reducing function and preparation method thereof |
-
2021
- 2021-06-24 CN CN202110706888.0A patent/CN113632855A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283386A (en) * | 2011-08-16 | 2011-12-21 | 中国林业科学研究院亚热带林业研究所 | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof |
| CN102318829A (en) * | 2011-08-17 | 2012-01-18 | 中国林业科学研究院亚热带林业研究所 | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof |
| CN103535710A (en) * | 2012-07-13 | 2014-01-29 | 杭州临安山妹子食品有限公司 | Pecan essential oil capsules and preparation method thereof |
| CN103392834A (en) * | 2013-08-14 | 2013-11-20 | 山东三星玉米产业科技有限公司 | Nutrition blend oil applicable to middle aged and elderly people and preparation method thereof |
| CN104958345A (en) * | 2015-07-14 | 2015-10-07 | 陈雨 | Soybean lecithin soft capsule with lipid-reducing function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283386B (en) | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof | |
| CN1160990A (en) | Food composition containing balancing agent for 'omega'-6 and 'omega'-3 unsaturated fatty acids | |
| Tarantul et al. | Spinach (lat. Spinacia oleracea) | |
| JP3001589B2 (en) | Lignan-containing foods and drinks | |
| CN101836725A (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| KR20150055876A (en) | Composition for reducing body-fat and weight | |
| CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
| CN105341184A (en) | Functional fat composition having effects of preventing cardiovascular and cerebrovascular diseases and diabetes risk factors | |
| CN113632855A (en) | Pecan oil composition with blood fat reducing function and preparation method thereof | |
| CN100402052C (en) | Blood fat-reducing medicine and its preparation method | |
| JPS61118318A (en) | Composition having improving action on serum lipid | |
| KR20120124037A (en) | Process for Preparing Milk Butter Containing Ajoene from Garlic | |
| CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| KR101611852B1 (en) | Food composition with Sancho seed oil for prevention or improvement of arteriosclerosis | |
| TW200300069A (en) | Anti-obesity foods and drinks | |
| KR20170029764A (en) | Garlic extracts, egg yolk extracts and sulfur mixture to back out of the prevention of cardiovascular, cerebrovascular and other circulatory organ system disease, for the inclusion of active ingredients and treatment of functional foods, improvement and the manufacturing method. and Health functional food, organic sulphur (MSM)as active ingredients composition | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| CN109393057A (en) | A kind of reducing blood lipid formula edible vegetable oil | |
| CN114028524B (en) | Compound for improving blood lipid metabolism and preparation method and application thereof | |
| CN107789398A (en) | A kind of pharmaceutical composition of Weight-reducing and lipid-lowering and preparation method thereof | |
| CN110638866B (en) | Antioxidant and anti-aging soft capsule | |
| EP4231849A1 (en) | Olive-derived compositions | |
| RU2362327C1 (en) | Moderately calorific mayonnaise | |
| Tabassum et al. | Buster Effect of Apricot Kernel Oil On Hypocholesteremia: Effect of Apricot Kernel Oil on Hypocholesteremia | |
| TWI297259B (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211112 |